Science image (IMAGE)
Caption
Stites challenged the prevailing idea that all cancer-associated KRAS gene mutations caused resistance to the available and effective anti-cancer drug cetuximab. His team was able to find and classify 10 drug-sensitive KRAS mutations (green). Also shown are some the drug-resistant mutations (red). Clinical trials could help match colorectal cancer patients with better treatment options, such as cetuximab, if they have drug-sensitive KRAS mutations.
Credit
Cell Reports and the Salk Institute
Usage Restrictions
with credit and related coverage.
License
Original content